Cantor Fitzgerald Analysts Give Allergan (AGN) a $180.00 Price Target

Cantor Fitzgerald set a $180.00 price target on Allergan (NYSE:AGN) in a research report sent to investors on Friday, January 4th. The firm currently has a hold rating on the stock.

AGN has been the topic of a number of other reports. Guggenheim initiated coverage on Allergan in a report on Monday, October 8th. They set a buy rating on the stock. ValuEngine downgraded Allergan from a sell rating to a strong sell rating in a report on Friday, December 21st. Credit Suisse Group set a $200.00 price objective on Allergan and gave the company a buy rating in a report on Thursday, December 13th. Raymond James decreased their price objective on Allergan from $232.00 to $198.00 and set a buy rating on the stock in a report on Wednesday, October 31st. Finally, Leerink Swann initiated coverage on shares of Allergan in a research note on Monday, November 12th. They issued an outperform rating and a $220.00 target price for the company. Two equities research analysts have rated the stock with a sell rating, five have given a hold rating and seventeen have issued a buy rating to the company’s stock. The company has an average rating of Buy and a consensus price target of $208.40.

NYSE AGN opened at $149.26 on Friday. Allergan has a fifty-two week low of $125.84 and a fifty-two week high of $197.00. The company has a debt-to-equity ratio of 0.32, a quick ratio of 0.78 and a current ratio of 0.92. The stock has a market cap of $48.77 billion, a price-to-earnings ratio of 9.13, a P/E/G ratio of 1.14 and a beta of 1.32.

Allergan (NYSE:AGN) last posted its earnings results on Tuesday, October 30th. The company reported $4.25 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $4.04 by $0.21. Allergan had a return on equity of 8.44% and a net margin of 14.50%. The company had revenue of $3.91 billion for the quarter, compared to analyst estimates of $3.89 billion. During the same period last year, the company earned $4.15 earnings per share. The business’s revenue was down 3.0% compared to the same quarter last year. Analysts anticipate that Allergan will post 16.52 earnings per share for the current fiscal year.

In related news, CFO Matthew M. Walsh acquired 1,000 shares of the company’s stock in a transaction that occurred on Friday, November 16th. The stock was purchased at an average price of $157.00 per share, for a total transaction of $157,000.00. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 0.37% of the company’s stock.

Hedge funds have recently made changes to their positions in the company. Morgan Stanley grew its holdings in shares of Allergan by 22.2% in the 3rd quarter. Morgan Stanley now owns 2,660,131 shares of the company’s stock valued at $506,702,000 after buying an additional 483,860 shares during the period. Nordea Investment Management AB acquired a new position in shares of Allergan in the 3rd quarter valued at $19,917,000. Eubel Brady & Suttman Asset Management Inc. grew its holdings in shares of Allergan by 1.5% in the 3rd quarter. Eubel Brady & Suttman Asset Management Inc. now owns 78,542 shares of the company’s stock valued at $14,961,000 after buying an additional 1,137 shares during the period. TPG Group Holdings SBS Advisors Inc. grew its holdings in shares of Allergan by 110.9% in the 2nd quarter. TPG Group Holdings SBS Advisors Inc. now owns 131,212 shares of the company’s stock valued at $21,876,000 after buying an additional 69,000 shares during the period. Finally, Wright Investors Service Inc. grew its holdings in shares of Allergan by 24.9% in the 3rd quarter. Wright Investors Service Inc. now owns 3,779 shares of the company’s stock valued at $720,000 after buying an additional 753 shares during the period. 78.13% of the stock is owned by institutional investors.

Allergan Company Profile

Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. It operates through US Specialized Therapeutics, US General Medicine, and International segments. The company offers a portfolio of products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology, and anti-infective therapeutic categories.

Further Reading: Moving Average – How it Helps Investors in Stock Selection

Analyst Recommendations for Allergan (NYSE:AGN)

Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply